10-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

Mon, Mar 3, 1:02 PM (48 days ago)

Artelo Biosciences, Inc. (ARTL) reported a net loss of $9.8 million for the fiscal year ending December 31, 2024, compared to $9.3 million in 2023. Operating expenses rose to $10.1 million from $9.9 million, primarily due to increased clinical trial costs, partially offset by higher R&D tax credits from the UK government. Cash and equivalents stood at $2.3 million, with working capital of $785,000, raising concerns about the company's ability to sustain operations without additional funding. The company has initiated clinical trials for key product candidates, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy, and is advancing its proprietary CBD cocrystal product. The company’s strategic focus on lipid-signaling modulation highlights its potential in addressing unmet medical needs. However, risks include dependence on third-party manufacturers, potential regulatory changes, and competition from established biopharmaceutical companies. Artelo's future outlook hinges on successful fundraising and clinical trial outcomes to achieve commercialization and profitability.